BB Biotech AG : Update post T1 2020 : Neutre réitéré, OC de 64 €
>Un T1 impacté par la pandémie COVID-19 - BB Biotech a publié vendredi dernier ses résultats du T1 2020, alors que le titre de la holding a reculé de 14.8% en € et de 15.7% en CHF sur le trimestre reflétant le sell-off sur les marchés consécutif à la pandémie COVID-19 (variations incluant le paiement des dividendes). La performance du portefeuille a reculé quant à elle de 22% en CHF, de 20.1% en € et de 21.4% en $ résultant en une perte nette de 758 MCHF sur la périod...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.